Nasrin Arbabi
Family Medicine · la Jolla, CANPI 1881655462
Payments from drug & device makers
Across 231 payments — averaging $51.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$2K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Lilly USA, LLC$780
- Bayer$661
- Biohaven Pharmaceuticals, Inc.$639
- plus $4K from 28 others
What the payments were for
- Consulting fees$1,20010%
- Travel & lodging$2552%
- Food & beverage$10,24487%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $2,382 |
| Novo Nordisk | 59 | $2,120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $1,699 |
| Lilly USA, LLC | 18 | $780 |
| Bayer | 15 | $661 |
| Biohaven Pharmaceuticals, Inc. | 8 | $639 |
| Amgen | 12 | $535 |
| AbbVie(2 entities) | 11 | $490 |
| Eisai Inc. | 3 | $253 |
| Actelion Pharmaceuticals US, Inc. | 2 | $227 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $178 |
| Teva Pharmaceuticals USA, Inc. | 3 | $155 |
| Astellas Pharma US Inc | 6 | $148 |
| Si-bone, Inc. | 1 | $147 |
| Sanofi Pasteur Inc. | 1 | $146 |
| Axsome Therapeutics, Inc. | 2 | $126 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Heartflow, Inc. | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Novartis | 5 | $114 |
| Intuitive Surgical | 1 | $108 |
| Merck | 1 | $100 |
| GSK | 3 | $80 |
| Pfizer | 4 | $69 |
| Inspire Medical Systems, Inc. | 2 | $55 |
| Jazz Pharmaceuticals Inc. | 2 | $40 |
| Therapeuticsmd, Inc. | 2 | $33 |
| IBSA Pharma Inc. | 1 | $31 |
| Mayne Pharma Commercial LLC | 1 | $25 |
| Phadia US Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Vertex | 1 | $17 |
| Exact Sciences | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,798 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 32 | $62,323 |
| OzempicSemaglutide | 46 | $52,504 |
| JanuviaSitagliptin Phosphate | 32 | $28,423 |
| FarxigaDapagliflozin Propanediol | 18 | $25,679 |
| EliquisApixaban | 27 | $22,143 |
| LinzessLinaclotide | 17 | $17,772 |
| JardianceEmpagliflozin | 18 | $14,916 |
| VascepaIcosapent Ethyl | 31 | $12,140 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,343 |
| Rosuvastatin Calcium | 193 | $3,741 |
| Icosapent Ethyl | 16 | $2,435 |
| Celecoxib | 16 | $2,347 |
| Losartan Potassium | 189 | $1,773 |
| Atorvastatin Calcium | 209 | $1,650 |
| Ipratropium Bromide | 50 | $1,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $2,120 | $114,82778 claims |
| MerckJanuvia | $100 | $28,42332 claims |
| AstraZenecaFarxiga | $2,382 | $25,67918 claims |
| PfizerEliquis | $69 | $22,14327 claims |
| AbbVieLinzess, Synthroid | $490 | $18,64433 claims |
| GSKBreo Ellipta | $80 | $4,34312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in la Jolla
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.